Atomwise Inc., invented the first deep learning AI technology for structure-based small molecule drug discovery, will partner with Hansoh Pharmaceutical Group Company Limited, a leading biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven target proteins in multiple therapeutic areas.
With the rising exciting science happening throughout Asia, and enormous potential for leadership in innovative drug discovery, Atomwise chose Hansoh Pharma as its first partner in Asia, which is committed to innovation and shares their mission for global impact on patient health.
Atomwise and Hansoh Pharma scientists will collaborate closely on all programs, by leveraging Atomwise’s AI technology and medicinal chemistry and protein structure expertise, and Hansoh Pharma’s fully integrated research and development, manufacturing and commercial capabilities. There is the potential to dramatically increase success and compress timelines for drug discovery and clinical development.
Under the terms of the collaboration, Atomwise will receive a package including: undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. According to historical average revenues for small molecule drugs, the total estimated value of the deal to Atomwise, if succeeded, in all projects could reach US$1.5 billion.